Exploring the Role of Eosinophils and IL-5 Inhibitors in Severe Asthma and Associated Conditions




Until recently, treatment options for severe asthma with an eosinophilic phenotype, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome were limited mostly to immunosuppression with oral corticosteroids (OCS) or other systemic agents. An expanding understanding of the pathophysiology of these diseases has led to the identification of newer therapeutic targets and more selective and better tolerated treatments for eosinophil reduction. This on-demand video activity with interactive case simulation and 3D animated images will review strategies for recognizing these phenotypes of severe eosinophilic diseases of the lungs and help the clinician better navigate available treatments in order to improve symptoms, lighten the disease burden, and reduce exacerbations and OCS reliance for patients with severe asthma and associated eosinophil-mediated conditions.


Led by expert faculty, this on-demand video activity will be conducted in the Practitioner’s Edge format and will employ interactive 3D models and a patient case study simulation to illustrate and reinforce key program objectives. The overall goal of the program is to provide information that is highly relevant to current practice and best-practice strategies.


Michael E. Wechsler, MD, MMSc (Program Chair)
Professor of Medicine
Director, Cohen Family Asthma Institute
National Jewish Health
Denver, Colorado


Bradley E. Chipps, MD
Medical Director
Capital Allergy and Respiratory Disease Center
Sacramento, California


Monica Kraft, MD
Robert & Irene Flinn Endowed Professor of Medicine
Chair, Department of Medicine
University of Arizona
Tucson, Arizona


Release date: September 21, 2020
Expiration date: September 21, 2021
Estimated time to complete activity: 1.25 hour(s)



This educational initiative is intended for allergists, pulmonologists, nurse practitioners, physician assistants, and other practitioners who manage patients with asthma and associated eosinophil-mediated conditions.


Upon completion of this educational activity, participants should be able to:

  • Describe the role of eosinophilia in severe asthma and EGPA
  • Explain why rare orphan diseases and severe asthma comorbidities have an impact on treatment of severe asthma
  • Differentiate between biologic therapies and evaluate their impact on lung function, disease exacerbation, and dependence on OCS

Physician Continuing Education

Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Integrity Continuing Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.


In order to receive credit for this online activity, the participant must complete the pretest and posttest, view the video, and complete the evaluation form. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher.


There is no fee for this educational activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.


Windows 7+
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.


Integrity Continuing Education requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.


Bradley E. Chipps, MD
Consultant: AstraZeneca, Boeringer Ingelheim, Genentech, Novartis, Regeneron, Sanofi Genzyme
Honoria (non-CME Services): AstraZeneca, Boeringer Ingelheim, Genentech, Novartis, Regeneron, Sanofi Genzyme

Monica Kraft, MD
Research: Association of Legal Administrators, AstraZeneca, Chiesi, and National Institutes of Health (funds paid to institution)
Royalty: Elsevier
Consultant: AstraZeneca, Sanofi

Michael E. Wechsler, MD, MMSc
Consulting Fees: Equillium, Genentech, Genzyme, GlaxoSmithKline, Regeneron, Sanofi, Teva


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


This CME activity is provided by Integrity Continuing Education.


This activity is supported by an educational grant from GlaxoSmithKline.


Continue to Pretest